Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma

被引：3
|
作者：
Ghatalia, Pooja [1 ]
Plimack, Elizabeth R. [1 ]
机构：
[1] Fox Chase Canc Ctr, Dept Hematol & Oncol, Philadelphia, PA 19111 USA
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2023年 / 20卷 / 12期
关键词：
CISPLATIN; CHEMOTHERAPY; CANCER; UNFIT;
D O I：
10.1038/s41571-023-00814-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the recent FDA Accelerated Approval of enfortumab vedotin (EV) plus pembrolizumab for patients with advanced-stage urothelial carcinoma who are cisplatin-ineligible, herein we highlight key clinical outcomes with this combination based on results from Cohort K of the pivotal phase Ib/II EV-103 trial. We also discuss treatment sequencing, de-escalation strategies and toxicity management as EV-pembrolizumab becomes widely used in clinical practice.
引用
收藏
页码：818 / 819
页数：2
相关论文
共 50 条
  • [41] Clinical significance of the dose modification of enfortumab vedotin monotherapy for advanced urothelial carcinoma
    Minato, Akinori
    Takaba, Tomohisa
    Sugita, Yoshihiro
    Kaneko, Yuya
    Hongyo, Ryota
    Tanaka, Toshinobu
    Bando, Taro
    Sugi, Takaomi
    Mizushima, Yui
    Matsukawa, Takuo
    Jojima, Kazumasa
    Higashijima, Katsuyoshi
    Nagata, Yujiro
    Tomisaki, Ikko
    Kashiwagi, Eiji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2025,
  • [42] Enfortumab vedotin and pembrolizumab. Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma
    Retz, Margitta
    Grimm, Marc-Oliver
    Leucht, Katharina
    Zschaebitz, Stefanie
    UROLOGIE, 2025, 64 (01): : 60 - 74
  • [43] Therapies After Progression on Enfortumab Vedotin and Pembrolizumab: Navigating Second-line Options for Metastatic Urothelial Carcinoma in the New Treatment Landscape
    Brown, Jason R.
    Koshkin, Vadim S.
    EUROPEAN UROLOGY FOCUS, 2024, 10 (02): : 231 - 233
  • [44] ARE STANDARD INDIRECT TREATMENT COMPARISON METHODS SUITABLE TO COMPARE FIRST-LINE VS MAINTENANCE THERAPIES? AN ASSESSMENT OF ENFORTUMAB VEDOTIN plus PEMBROLIZUMAB VS AVELUMAB IN LOCALLY ADVANCED/METASTATIC UROTHELIAL CARCINOMA
    Dillon, R.
    Wilson, F.
    Chan, K.
    McLoone, D.
    Kodi, E.
    Pepper, A. N.
    Shih, V
    Keeping, S.
    VALUE IN HEALTH, 2024, 27 (06) : S42 - S42
  • [45] A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab
    Hoimes, Christopher J.
    Flaig, Thomas W.
    Milowsky, Matthew, I
    Friedlander, Terence W.
    Bilen, Mehmet Asim
    Gupta, Shilpa
    Srinivas, Sandy
    Merchan, Jaime R.
    Mckay, Rana R.
    Petrylak, Daniel P.
    Sasse, Carolyn
    Moreno, Blanca Homet
    Yu, Yao
    Carret, Anne-Sophie
    Rosenberg, Jonathan E.
    FUTURE ONCOLOGY, 2024, 20 (07) : 351 - 360
  • [46] Comparison of the efficacy of enfortumab vedotin and paclitaxel plus carboplatin in patients with metastatic urothelial carcinoma
    Nakagawa, Ryunosuke
    Izumi, Kouji
    Toriumi, Ren
    Aoyama, Shuhei
    Kano, Hiroshi
    Makino, Tomoyuki
    Naito, Renato
    Kadomoto, Suguru
    Iwamoto, Hiroaki
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Mizokami, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2025, 30 (03) : 524 - 531
  • [47] Enfortumab Vedotin for Elderly Advanced Urothelial Carcinoma Patients or Those With a Poor Performance Status
    Furubayashi, Nobuki
    Minato, Akinori
    Tomoda, Toshihisa
    Masaoka, Hiroyuki
    Hori, Yoshifumi
    Kiyoshima, Keijiro
    Negishi, Takahito
    Haraguchi, Yusuke
    Koga, Toshiki
    Song, Yoohyun
    Harada, Kenichi
    Kuroiwa, Kentaro
    Seki, Narihito
    Fujimoto, Naohiro
    Nakamura, Motonobu
    ANTICANCER RESEARCH, 2024, 44 (08) : 3409 - 3417
  • [48] Efficacy and safety of routine corticosteroid premedication in enfortumab vedotin therapy for advanced urothelial carcinoma
    Hara, Takuto
    Suzuki, Kotaro
    Tobe, Taisuke
    Ueki, Hideto
    Wakita, Naoto
    Okamura, Yasuyoshi
    Bando, Yukari
    Terakawa, Tomoaki
    Hyodo, Yoji
    Chiba, Koji
    Teishima, Jun
    Yao, Akihisa
    Miyake, Hideaki
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2025,
  • [49] AUO Perioperative Use of Pembrolizumab plus Enfortumab Vedotin in Muscle-invasive Bladder Carcinoma
    Rexer, H.
    Merseburger, A.
    UROLOGIE, 2023, 62 (11): : 1262 - 1263
  • [50] Enfortumab vedotin plus pembrolizumab as a first-line treatment for advanced urothelial carcinoma: a cost-effectiveness analysis from China based on the EV-302 trial
    You, Maojin
    Zheng, Qiaoyan
    He, Ying
    FRONTIERS IN PHARMACOLOGY, 2024, 15
12345